nab-paclitaxel

Details

Files

Generic Name:

nab-paclitaxel

Project Status:

Pending

Therapeutic Area:

Gastrointestinal cancer

Manufacturer:

N/A

Call for patient/clinician input open:

February 29, 2024

Brand Name:

N/A

Project Line:

Reimbursement Review

Project Number:

PX0360-000

Call for patient/clinician input closed:

April 22, 2024

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

N/A

Submission Type:

Non-sponsored Submission

Fee Schedule:

Pending

Indications:

In combination with gemcitabine for the adjuvant treatment of pancreatic cancer.

Anticipated Date:

February 12, 2024

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Last Updated : February 29, 2024